ROCHESTER, Minn. -- Researchers at Mayo Clinic have identified the enzyme, called CD38, that is responsible for the decrease in nicotinamide adenine dinucleotide (NAD) during aging, a process that is associated with age-related metabolic decline. Results demonstrated an increase in the presence of CD38 with aging in both mice and humans. The results appear today in Cell Metabolism.
"As we age, we experience a decline in our metabolism and metabolic function. This increases the incidence of age-related metabolic diseases like obesity, diabetes and others," says Eduardo Chini, M.D., Ph.D., anesthesiologist and researcher for Mayo Clinic's Robert and Arlene Kogod Center on Aging and lead author of the study. "Previous studies have shown that levels of NAD decline during the aging process in several organisms. This decrease in NAD appears to be, at least in part, responsible for age-related metabolic decline."
In this study, researchers at the Center on Aging have shown that CD38, an enzyme that is present in inflammatory cells, is directly involved in the process that mediates the age-related NAD decline. Comparing 3- to 32-month-old mice, researchers found that levels of CD38 increased at least two to three times during chronological aging in all tissues tested, including the liver, fat, spleen and skeletal muscle.
To determine if the increase in CD38 observed in mice was also present in humans, researchers compared the levels in groups of individuals who were approximately 34-years-old to groups of individuals who were approximately 61-years-old. Similar to their observations in mice, researchers found that CD38 increased up to two-and-a-half times in the fat tissue of older individuals.
"The future of our research will be to develop compounds that can inhibit the function of CD38 to increase NAD levels during aging," says Dr. Chini. "We are also investigating the mechanisms that lead to the increase in CD38 during the aging process."
While further studies are needed, Dr. Chini believes that these findings are a critical step toward the development of therapies needed for age-related metabolic dysfunction, which includes conditions such as obesity and diabetes.
The research was supported by the American Federation for Aging Research, the Mayo Foundation, the Strickland Career Development Award, National Institutes of Health, National Institute of Aging, National Institute of Diabetes and Digestive and Kidney Diseases, Mayo-University of Minnesota Decade of Discovery, Minnesota Obesity Council, and the Conselho Nacional de Desenvolvimento Científico e Tecnológico/Brazil and Fundac?ão de Amparo é Pesquisa do Rio de Janeiro/Brazil.
Others on the research team include Juliana Camacho-Pereira, Mariana Guedes Tarragó, M.D., Claudia Chini, Ph.D., Veronic Nin, Carlos Escande, Gina Warner, Amrutesh Puranik, Ph.D., Renee Schoon and Joel Reid, Ph.D., of Mayo Clinic, as well as Juliana Camacho-Pereira and Antonio Galina of theUniversidade Federal do Rio de Janeiro, Cidade Universitária.
About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to clinical practice, education and research, providing expert, whole-person care to everyone who needs healing. For more information, visit http://www.